Evolución del consumo de fármacos específicos para la demencia en la comunidad autónoma de Madrid durante el periodo 2002-2012
- 1 September 2015
- journal article
- Published by Elsevier in Neurología
- Vol. 30 (7) , 416-424
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Donepezil and Memantine for Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2012
- ¿Cuándo suspender el tratamiento farmacológico específico en el Alzheimer?Atencion Primaria, 2011
- Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for PsychopharmacologyJournal of Psychopharmacology, 2010
- The economic impact of dementia in Europe in 2008—cost estimates from the Eurocode projectInternational Journal of Geriatric Psychiatry, 2010
- Prospective One-Year Cost-of-Illness Study in a Cohort of Patients with Dementia of Alzheimer's Disease Type in Spain: The ECO StudyJournal of Alzheimer’s Disease, 2010
- Prevalence of dementia and major dementia subtypes in Spanish populations: A reanalysis of dementia prevalence surveys, 1990-2008BMC Neurology, 2009
- The Cost of Dementia in EuropePharmacoEconomics, 2009
- Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementiaCanadian Medical Association Journal, 2008
- Análisis de los costes de la enfermedad de Alzheimer en función del deterioro cognitivo y funcionalMedicina Clinica, 2004